• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

MannKind Corporation - Common Stock (NQ:MNKD)

4.050 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 227
Open 4.050
Bid (Size) 4.010 (100)
Ask (Size) 4.070 (600)
Prev. Close 4.050
Today's Range 4.050 - 4.050
52wk Range 2.230 - 6.510
Shares Outstanding 264,305,532
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
MannKind Awarded Breakthrough T1D Grant to Support Advancement of INHALE-1ST Pediatric Trial of Afrezza® in Youth with Newly-Diagnosed T1D
June 23, 2026
From MannKind
Via GlobeNewswire
News headline image
Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind’s Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with Automated Insulin Delivery (AID) Systems
June 05, 2026
From MannKind
Via GlobeNewswire

Performance

YTD
-27.7%
-27.7%
1 Month
+14.7%
+14.7%
3 Month
+59.4%
+59.4%
6 Month
-28.6%
-28.6%
1 Year
+13.1%
+13.1%

More News

Read More
News headline image
MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2 Trial for Nintedanib DPI in Patients with IPF
June 03, 2026
From MannKind
Via GlobeNewswire
MannKind Corp (NASDAQ:MNKD) Q1 2026 Revenue Miss and Wider EPS Loss Overshadow Strong Pipeline Progress ↗
May 06, 2026
Via Chartmill
MannKind Corp (NASDAQ:MNKD) Reports Q4 2025 Revenue Beat and Strategic Outlook for 2026 ↗
February 26, 2026
Via Chartmill
News headline image
MannKind Wins FDA Approval for Afrezza in Children, Opening Pediatric Diabetes Market ↗
May 30, 2026
Via MarketBeat
News headline image
MannKind to Host Conference Call Today to Discuss Afrezza Pediatric Approval
May 29, 2026
From MannKind
Via GlobeNewswire
News headline image
MannKind Announces FDA Approval of Afrezza®, the First and Only Inhaled Mealtime Insulin for Use in Children and Adolescents Aged 6 and Older Living with Diabetes
May 29, 2026
From MannKind
Via GlobeNewswire
News headline image
MannKind to Present at Jefferies Global Healthcare Conference
May 27, 2026
From MannKind
Via GlobeNewswire
News headline image
MannKind to Showcase New Data at ADA 2026 Advancing Understanding of Inhaled Insulin (Afrezza®) in Pediatric Care, Pregnancy and Use with Automated Insulin Delivery (AID) Systems
May 27, 2026
From MannKind
Via GlobeNewswire
News headline image
MannKind (MNKD) Q1 2026 Earnings Transcript ↗
May 06, 2026
Via The Motley Fool
News headline image
MannKind Reports First Quarter 2026 Financial Results and Provides Business Update
May 06, 2026
From MannKind
Via GlobeNewswire
Keep an eye on the top gainers and losers in Wednesday's session. ↗
May 06, 2026
Via Chartmill
Wednesday's session: gap up and gap down stocks ↗
May 06, 2026
Via Chartmill
News headline image
MannKind Announces Ralinepag Dry Powder Inhalation (DPI) Program to be Pursued for Pulmonary Hypertension and Fibrotic Lung Diseases
May 06, 2026
From MannKind
Via GlobeNewswire
News headline image
MannKind to Report First Quarter 2026 Financial Results on May 6, 2026
April 29, 2026
From MannKind
Via GlobeNewswire
News headline image
MannKind to Present New Data From Pediatric and Adult Studies of Afrezza® at ATTD 2026
March 09, 2026
From MannKind
Via GlobeNewswire
News headline image
MannKind Announces Settlement of Convertible Senior Notes
March 05, 2026
From MannKind
Via GlobeNewswire
News headline image
MannKind to Participate in Upcoming Investor Conferences
March 04, 2026
From MannKind
Via GlobeNewswire
News headline image
What's Going On With MannKind Stock Friday? ↗
February 27, 2026
Via Benzinga
News headline image
Why MannKind Stock Tumbled on Thursday ↗
February 26, 2026
Via The Motley Fool
News headline image
MannKind Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
February 26, 2026
From MannKind
Via GlobeNewswire
Let's take a look at the stocks that are in motion in today's session. ↗
February 25, 2026
Via Chartmill
News headline image
MannKind Stock Plummets After Partner United Therapeutics Unveils New ‘Category Killer Product’ ↗
February 25, 2026
Via Stocktwits
Here are the top movers in Wednesday's session. ↗
February 25, 2026
Via Chartmill

Frequently Asked Questions

Is MannKind Corporation - Common Stock publicly traded?
Yes, MannKind Corporation - Common Stock is publicly traded.
What exchange does MannKind Corporation - Common Stock trade on?
MannKind Corporation - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for MannKind Corporation - Common Stock?
The ticker symbol for MannKind Corporation - Common Stock is MNKD on the Nasdaq Stock Market
What is the current price of MannKind Corporation - Common Stock?
The current price of MannKind Corporation - Common Stock is 4.050
When was MannKind Corporation - Common Stock last traded?
The last trade of MannKind Corporation - Common Stock was at 07/01/26 04:00 PM ET
What is the market capitalization of MannKind Corporation - Common Stock?
The market capitalization of MannKind Corporation - Common Stock is 1.07B
How many shares of MannKind Corporation - Common Stock are outstanding?
MannKind Corporation - Common Stock has 1B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap